Free Trial

Coherus BioSciences (CHRS) Competitors

Coherus BioSciences logo
$0.75 -0.03 (-3.37%)
As of 12:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CHRS vs. CGEM, ETON, ALT, SANA, MGTX, MAZE, SIGA, ZVRA, SAGE, and AMLX

Should you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Cullinan Therapeutics (CGEM), Eton Pharmaceuticals (ETON), Altimmune (ALT), Sana Biotechnology (SANA), MeiraGTx (MGTX), Maze Therapeutics (MAZE), SIGA Technologies (SIGA), Zevra Therapeutics (ZVRA), Sage Therapeutics (SAGE), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.

Coherus BioSciences vs.

Coherus BioSciences (NASDAQ:CHRS) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment.

Coherus BioSciences presently has a consensus target price of $4.68, suggesting a potential upside of 504.22%. Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 305.58%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than Cullinan Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coherus BioSciences
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Cullinan Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Coherus BioSciences and Coherus BioSciences both had 4 articles in the media. Cullinan Therapeutics' average media sentiment score of 1.10 beat Coherus BioSciences' score of 0.69 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coherus BioSciences
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cullinan Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Coherus BioSciences received 403 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 83.93% of users gave Cullinan Therapeutics an outperform vote while only 64.94% of users gave Coherus BioSciences an outperform vote.

CompanyUnderperformOutperform
Coherus BioSciencesOutperform Votes
450
64.94%
Underperform Votes
243
35.06%
Cullinan TherapeuticsOutperform Votes
47
83.93%
Underperform Votes
9
16.07%

Cullinan Therapeutics has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coherus BioSciences-0.15% N/A -24.44%
Cullinan Therapeutics N/A -26.54%-25.32%

Coherus BioSciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.

Cullinan Therapeutics has lower revenue, but higher earnings than Coherus BioSciences. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coherus BioSciences$272.25M0.33-$237.89M-$1.13-0.69
Cullinan TherapeuticsN/AN/A-$153.16M-$2.91-2.71

72.8% of Coherus BioSciences shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.1% of Coherus BioSciences shares are held by company insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Coherus BioSciences and Cullinan Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Coherus BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHRS vs. The Competition

MetricCoherus BioSciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$89.86M$2.93B$5.33B$8.39B
Dividend YieldN/A1.64%5.21%4.11%
P/E Ratio-9.6931.1826.7119.71
Price / Sales0.33398.78386.46120.65
Price / CashN/A168.6838.2534.62
Price / Book-0.453.236.774.50
Net Income-$237.89M-$72.35M$3.23B$248.22M
7 Day Performance1.85%2.49%0.48%-0.78%
1 Month Performance-30.17%2.45%9.10%11.53%
1 Year Performance-61.44%-24.98%18.56%8.99%

Coherus BioSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHRS
Coherus BioSciences
3.6716 of 5 stars
$0.75
-3.4%
$4.68
+525.3%
-63.3%$86.83M$272.25M-9.36330Analyst Downgrade
Gap Down
CGEM
Cullinan Therapeutics
2.3873 of 5 stars
$7.91
+4.9%
$32.00
+304.6%
-65.9%$466.81MN/A-2.7930
ETON
Eton Pharmaceuticals
2.3835 of 5 stars
$17.35
+3.3%
$27.67
+59.5%
+453.3%$465.29M$39.01M-78.8620Positive News
High Trading Volume
ALT
Altimmune
2.4726 of 5 stars
$6.01
+7.5%
$20.20
+236.1%
-26.9%$462.85M$20,000.00-3.8850Analyst Upgrade
Gap Up
SANA
Sana Biotechnology
2.4303 of 5 stars
$2.00
+9.9%
$10.80
+440.0%
-75.8%$450.95MN/A-1.43380Gap Down
High Trading Volume
MGTX
MeiraGTx
4.5668 of 5 stars
$5.62
+3.7%
$24.50
+335.9%
-10.6%$449.33M$33.28M-4.64300Analyst Downgrade
MAZE
Maze Therapeutics
N/A$10.13
+5.3%
$25.67
+153.4%
N/A$443.65M$167.50M0.00121Gap Up
SIGA
SIGA Technologies
1.1589 of 5 stars
$5.94
+4.9%
N/A-21.9%$424.36M$138.72M4.9540Positive News
ZVRA
Zevra Therapeutics
3.2331 of 5 stars
$7.75
-1.5%
$22.29
+187.6%
+85.1%$423.76M$23.61M-3.9320Analyst Upgrade
SAGE
Sage Therapeutics
3.8332 of 5 stars
$6.75
+2.9%
$8.81
+30.6%
-45.4%$422.69M$47.40M-1.02690Gap Up
AMLX
Amylyx Pharmaceuticals
3.44 of 5 stars
$4.60
-0.2%
$9.67
+110.1%
+192.9%$409.79M$-1,272,000.00-1.20200

Related Companies and Tools


This page (NASDAQ:CHRS) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners